Phosphocreatine (PCr) plays an important role in the energy metabolism of the heart and a decrease in its intracellular concentration results in alteration of myocardium energetics and work. We conducted a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with coronary artery disease or chronic heart failure or in those undergoing cardiac surgery. We systematically searched PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials and Google Scholar up to 1 November 2015, for pertinent trials. The primary outcome was all-cause mortality. Secondary outcomes included inotrope use, ejection fraction (EF), peak creatinine kinase-myocardial band (CK-MB) release and the incidence of major arrhythmias, as well as spontaneous recovery of the heart performance in the subgroup of patients undergoing cardiac surgery with cardiopulmonary bypass. We pooled odds ratio (OR) and mean difference (MD) using fixed-and random effects models. We identified 41 controlled trials, of them 32 were randomized. Patients receiving PCr had lower all-cause mortality when compared with the control group [61/1731 (3.5%) vs 177/1667 (10.6%); OR: 0.71, 95% CI: 0.51-0.99; P = 0.04; I 2 = 0%; with 3400 patients and 22 trials included]. Phosphocreatine administration was associated with higher LVEF (MD: 3.82, 95% CI: 1.18-6.46; P = 0.005; I 2 = 98%), lower peak CK-MB release (MD: −6.08, 95% CI: −8.01, −4.15; P < 0.001; I 2 = 97%), lower rate of major arrhythmias (OR: 0.42; 95% CI: 0.27-0.66; P < 0.001; I 2 = 0%), lower incidence of inotropic support (OR: 0.39, 95% CI: 0.25-0.61; P < 0.001; I 2 = 56%) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95% CI: 2.28-5.35; P < 0.001; I 2 = 49%) when compared with the control group. In a mixed population of patients with coronary artery disease, chronic heart failure or in those undergoing cardiac surgery, PCr may reduce all-cause short-term mortality. In addition, PCr administration was associated with improved cardiac outcomes. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large multicentre randomized trial to confirm these findings.
INTRODUCTION
Phosphocreatine (PCr) is a key component in the intracellular system of energy buffering and transport from the site of energy production to the site of energy utilization to ensure that supply meets the high and dynamic demands of the heart [1, 2] . Particularly, PCr makes energy of phosphoryl bonds of adenosine triphosphate (ATP) available at the myofibrillar creatine kinase that allows myocardium contraction [1, 2] . A consistent experimental evidence found that in chronic heart failure (CHF) and acute ischaemia, there are both gradual loss of component of the energy transport system and reduction in its activity [3] [4] [5] .
Supplementation with PCr was, therefore, suggested as potentially beneficial in patients with acute and chronic myocardial ischaemic injury [6, 7] . Several studies demonstrated that PCr use has protective effects in different clinical settings, including cardiac surgery, myocardial infarction, CHF, skeletal muscle hypotonotrophy and cerebral ischaemia [6] . When the studies investigating PCr administration in patients with heart failure and coronary artery disease (CAD) were analysed, they seem to improve dysrhythmia and dyspnoea [7] . There is still uncertainty, however, whether the administration of PCr affects the clinically important outcomes for the above-mentioned conditions. Moreover, systemic evaluation of the evidence for the effectiveness of PCr is restricted by the clinical context of heart failure and CAD and lacking for cardiac surgery.
Since all previous studies investigated secondary end-points and none of them was powered enough to obtain results on survival, we performed a meta-analysis of all randomized and matched trials that compared PCr with placebo or standard treatment in patients with CAD or CHF or in those undergoing cardiac surgery to investigate its effect on survival. We hypothesized that PCr would reduce all-cause mortality in patients with acute and chronic heart disease when compared with placebo or standard treatment.
MATERIALS AND METHODS

Search strategy
We conducted a systematic review following the PRISMA statement [8] . We carried out an electronic search in PubMed/Medline, Embase, Scopus, Cochrane Central Register of Controlled Trials databases and Google Scholar up to 1 November 2015. We used a combination of relevant keywords to construct the search strategy including PCr, phosphorylcreatine, creatine phosphate, neoton, randomized and controlled trial (Supplementary Digital Content). Two authors conducted the first screening of potentially relevant records based on titles and abstract, then independently performed the final selection of included trials based on full-text evaluation. Citation tracking was also performed on included studies and relevant reviews, and relevant clinical trials registries were searched for ongoing and unpublished studies. We also contacted the producer of the PCr originator (Alfa Wassermann S.p.A., Italy) to identify further studies. Consensus between the two reviewers was used to resolve any disagreement.
Studies were included if they met all the following criteria: evaluated PCr versus placebo or standard treatment among adult and paediatric patients with CAD, CHF or in those undergoing cardiac surgery; reported mortality ( primary outcome) or inotropes use, left ventricular ejection fraction (LVEF), creatinine kinase-myocardial band (CK-MB) and troponin I (TnI) release, the incidence of major arrhythmias (ventricular fibrillation and tachycardia), defibrillation, as well as spontaneous recovery of the heart performance after cardiopulmonary bypass in patients undergoing cardiac surgery (secondary outcomes); were randomized controlled trials (RCTs), control studies (studies in which patients were allocated to different interventions using methods that were not random) or case-matched studies (studies in which controls were enrolled to match the characteristics of the cases). Our search was not restricted to studies in the English language.
Data extraction and quality assessment
Two authors extracted all relevant information from the included studies and entered the data into an electronic data sheet specifically designed for this study with discrepancies resolved by consensus with a third author. When in a study there was more than one group of patients receiving PCr (e.g. different doses), we united them and considered them as a single treatment group. We contacted the authors of original studies when data were missing. If the authors could not provide the required information or did not answer on our inquiries, for analysis of the primary and secondary outcomes, we used only the reported data from retrieved manuscripts, their supplementary materials and, when appropriate, from the previous review in the field [7] .
We used the Cochrane Collaboration's tool to assess risk of bias [9] .
Data analysis
All analyses were performed according to the intention-to-treat principle. The Mantel-Haenszel method was used to pool dichotomous data and to compute pooled odds ratio (OR) with 95% confidence intervals (CI). The inverse variance method was used to pool continuous data and to calculate mean differences (MDs) with 95% CI. When continuous variables were reported as median and inter-quartile range, we transformed the data using the following formula: mean = median, standard deviation = (third quartile − first quartile)/1.35 to avoid losing data [9] . We tested for heterogeneity using the Q statistic and quantified it with the I 2 statistic [9] . We used the random effects model in all cases except those when the I 2 test was equal 0% where we employed the fixed effect model (heterogeneity close to zero was approximated to 0% by the statistical software). We also calculated the number needed to treat (NNT). We performed subgroup analyses of mortality including only RCTs. We also performed subgroup analyses for several secondary outcomes including surgical patients only, CAD patients only or CHF patients only. Risk of publication bias was evaluated by visual inspection of funnel plot. The significance level was set at 0.007 for all analyses among secondary outcomes according to the number of the analyses conducted. Meta-analysis was performed using Review Manager (RevMan, Version 5.3., Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014).
RESULTS
Characteristics of included studies
Of 4182 articles screened, 41 studies met inclusion criteria and 5069 patients were included (Fig. 1 , Supplementary Digital Content) . There were 32 RCTs with 3629 patients [10, 12-16, 18-24, 26-32, 34-36, 40-47, 49] , 4 controlled trials with 610 patients [11, 33, 38, 39] and 5 case-matched studies with 830 patients [17, 25, 37, 48, 50] (Table 1) . Twenty-three studies assessed Myocardial infarction with Q wave IV 2-4 g by bolus before thrombolysis then IV infusion of 8-16 g in 200 ml glycose 5% within 2 h after thrombolysis then IV infusion of 2-4 g in 50 ml of saline twice a day on the second day of myocardial infarction then IV infusion of 2 g in 50 ml of saline twice a day on the third and the sixth day of myocardial infarction [20] . Two studies of CABG setting included only patients with low LVEF [11, 27] , and one study also included off-pump cases [24] . Among the included trials, there was one study in paediatric setting [20] and another one also included congenital cases [45] . [13, 49] . Five studies were presented as conferences proceedings [20, 22, 39, 45, 50] .
Most included trials were at unclear or high risk of bias according to the Cochrane criteria (Supplementary Table 1 and Fig. 1 ).
Quantitative data synthesis
Mortality was reduced in the PCr group when compared with control [61/1731 (3.5%) vs 177/1667 (10.6%); OR: 0.71, 95% CI: 0.51-0.99; P for effect = 0.04; NNT = 14] without heterogeneity (P for heterogeneity = 0.92; I 2 = 0%) and 23 trials included (Fig. 2) . The length of follow-up never exceeds hospital stay (Supplementary Table 2 ). Visual inspection of the funnel plot did not reveal publication bias (Supplementary Fig. 2 ). Magnitude and direction of the mortality reduction were confirmed in the subgroup analysis that included only the 17 RCTs even if the statistically significance was lost (Supplementary Fig. 3 ). Baseline clinical, instrumental and laboratory data were well matched in all non-RCTs (Supplementary Digital Content). Moreover, pooled baseline characteristics (age, sex and LVEF in the overall population and length of cardiopulmonary bypass and aortic crossclamping in the cardiac surgical population) were well matched (Supplementary Figs 4-8) . When performing subgroup analyses in surgical (OR: 0.80), CAD (0.71) or CHF (OR 0.40) settings, the magnitude and direction of the effect on mortality was confirmed (Supplementary Figs 9-11) .
Administration of PCr was associated with enhancement in post-administration LVEF (MD: 3.82, 95% CI: 1.18-6.46; P for effect = 0.005; P for heterogeneity < 0.001; I 2 = 98%; with 10 included trials; Fig. 3 ), lower peak CK-MB release (MD: −6.08, 95% CI: −8.01, −4.15; P for effect < 0.001; P for heterogeneity < 0.001; I 2 = 97%; with 11 included trials; Fig. 4 ) and lower peak TnI concentration (MD: −45.59, 95% CI: −50.97, −40.22; P for effect < 0.001; P for heterogeneity < 0.001; I 2 = 100%; with three included trials; Supplementary Fig. 12 ) when compared with the control group. In most cases, the subgroup analyses (surgical, CAD or CHF trials) Tronconi L [45] The study included the same patients as in Samarenko [41] .
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confirmed the beneficial effects of PCr on LVEF improvement, lower peak CK-MB and peak TnI release (Supplementary Figs 13-19 ). The PCr group in cardiac surgery patients had a significant reduction in the incidence of major arrhythmias (11.9 vs 21.6%; OR: 0.42, 95% CI: 0.27-0.66; P for effect < 0.001; P for heterogeneity < 0.78; I 2 = 0% with 13 trials included; Fig. 5 ), inotropes use (OR: 0.39, 95% CI: 0.25-0.61; P for effect < 0.001; P for heterogeneity = 0.004; I 2 = 56%; with 15 included trials; Fig. 6 ) and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass (OR: 3.49, 95% CI: 2.28-5.35; P for effect < 0.001; P for The difference in the need for defibrillation (20.6 vs 64.8%; OR: 0.25, 95% CI: 0.07-0.87; P for effect = 0.03; P for heterogeneity < 0.001; I 2 = 88% with six trials included; Supplementary Fig. 26 ) was not significant according to the pre-specified level for statistical significance (P < 0.007) due to the Bonferroni correction for multiple comparison among the secondary outcomes.
DISCUSSION
The most important finding of our meta-analysis is that PCr use may be associated with improved short-term survival in patients with CAD, CHF or in those undergoing cardiac surgery. Treatment with PCr also resulted in the enhancement of LVEF in cardiac surgical and CHF patients, lower peak CK-MB release in cardiac surgical and CAD patients and lower TnI release in cardiac surgical patients when compared with controls. In heart surgery patients, administration of PCr was also associated with a reduction in the incidence of major arrhythmias, inotropes use and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass when compared with the control group.
The mechanism of action linking the improvement in heart function with PCr use could be explained by several potential protective effects of the drug. There are numerous experimental studies showing that PCr is an essential metabolite in the network of energy transfer in the cardiomyocytes [2, 51] . Particularly, creatine interacts with ATP with the help of creatine kinase enzyme to take the third phosphoryl group and to yield PCr. The energy within phosphoryl bond is transported by PCr to the sites of energy consumption, including myosin ATPase that in turn provides energy for actomyosin contraction [2, 51, 52] . Loss of PCr or decrease in enzymes activity responsible for PCr synthesis and utilization in the heart results in contractile dysfunction [1, 53] . Down-regulation of the creatine transporter system in the cell membrane is considered as one of the main contributors for the lowering of PCr intracellular content [54] . In a mice model with undetectable levels of PCr and creatine, it was demonstrated that hearts with a severely reduced capacity of the CK/PCr system show limited inotropic reserve and aggravated injury after acute stress [5] . Opposite experimental model in mice with overexpressed creatine transporter in the heart documented protection 
STATE-OF-THE-ART
against ischaemic/reperfusion injury in vivo (average 27% less myocardial necrosis) and improved functional recovery following ex vivo ischaemic/reperfusion injury [55] . Bottomley et al. [56] by using magnetic resonance spectroscopy in 58 patients with non-ischaemic cardiomyopathy within median follow-up of 4.7 years showed that creatine kinase flux is an independent predictor of all-cause and cardiovascular mortality. Driven by the rationale that augmentation or stimulation of the energy transport system has a therapeutic promise, several experimental models consistently demonstrated that the treatment with exogenous PCr provides protection for ischaemic myocardium, decreasing the size and severity of ischaemia [57] [58] [59] [60] . The experimental evidence that PCr has protective effects against ischaemia seems to be universal since a series of studies showed that PCr and creatine can also decrease the morphological damage and the neuron apoptosis of the ischaemia-reperfusion brain injury [61] [62] [63] .
Another possible effects of PCr could be linked to membrane stabilization. Using different experimental models, TokarskaSchlattner et al. [64] demonstrated that PCr can directly bind to membrane phospholipids, change structural and conformational characteristics of phospholipids and, by means of this, can protect membrane from leakage induced by a cell membrane lytic factors.
In our meta-analysis, we investigated the clinical use of PCr in patients with acute and chronic heart pathology, including those exposed to cardiac surgery stress. The heart as a hydraulic pump is an organ that adjusts its work constantly changing oxygen and metabolic tissue requirements. To provide this function, the heart has high and dynamic energy demands that require readily available substrates for energy production, transportation and utilization [1] . PCr plays the central role in the process of energy buffering and transfer in the heart [2] . Our meta-analysis is the first and largest one to report evidence of favourable changes in cardiac outcomes (LVEF, CK-MB and TnI release, major arrhythmias, as well as inotrope use and spontaneous recovery of the heart after cardiopulmonary bypass in cardiac surgery patients). Most importantly, it is the first time that an effect on survival is suggested in patients with acute and chronic myocardial ischaemia.
Our study could be compared only with two previously published reviews. In 2011, the Cochrane group published a meta-analysis that included 1474 adult patients with heart failure and ischaemic heart disease from 11 RCTs [7] and they found improvement in the rate of dysrhythmia and dyspnoea episodes. We added 30 additional studies and this allowed us to better investigate the effects of PCr on clinically relevant outcomes (e.g. survival). Another review by Strumia et al. [6] summarized the research carried out over a 40-year period on PCr and updated on October 2011 in different clinical settings, including acute and chronic heart pathology, skeletal muscle hypotrophy and cerebral ischaemia. However, the conclusions of this manuscript were limited by the narrative character of the review and the heterogeneity of the studied settings.
The major limitation of our study is that most of the included studies had an unclear or high risk of bias according to the Cochrane criteria [9] . However, for the primary outcome (mortality), we had pooled estimate without heterogeneity that indicates coincidence of the included trial results. Secondary outcomes had high heterogeneity of pooled estimates, but the visual inspection of the forest plots revealed common direction of the effects with the only difference in the magnitude. Notably, we performed conservative correction of P-value for multiple comparison when analysing the secondary outcomes. Importantly, when we analysed baseline data such as age, sex, baseline LVEF, and, for surgical patients also length of cardiopulmonary bypass, and of aortic cross-clamping, we did not find any difference.
In conclusion, the present meta-analysis demonstrated that the treatment with PCr in patients with acute and chronic heart disease may reduce all-cause short-term mortality. Furthermore, the use of PCr was associated with improvement in LVEF in surgical and CHF patients, lower peak CK-MB release in surgical and CAD patients and lower peak TnI release in surgical patients. In heart surgery patients, PCr was also associated with a reduction in major arrhythmias, inotrope use and a higher level of spontaneous recovery of the heart performance after cardiopulmonary bypass when compared with the control group. Owing to the pharmacological plausibility of this effect and to the concordance of the beneficial effects of PCr on several secondary but important outcomes and survival, there is urgent need for a large high-quality multicentre randomized trial to confirm these findings. SUPPLEMENTARY MATERIAL
